Claims for Patent: 9,382,327

Summary for Patent: 9,382,327

Title:	Anti-CD20 antibodies and methods of use
Abstract:	Compositions and methods are provided for treating diseases associated with CD20, including lymphomas, autoimmune diseases, and transplant rejections. Compositions include anti-CD20 antibodies capable of binding to a human CD20 antigen located on the surface of a human CD20-expressing cell, wherein the antibody has increased complement-dependent cell-mediated cytotoxicity (CDC) that is achieved by having at least one optimized CDR engineered within the variable region of the antibody. Compositions also include antigen-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The invention further includes pharmaceutical compositions comprising the anti-CD20 antibodies of the invention, or antigen-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier, and methods of use of these anti-CD20 antibodies.
Inventor(s):	Smith; Ernest S. (Rochester, NY), Fisher, Jr.; Terrence L. (Rochester, NY)
Assignee:	VACCINEX, INC. (Rochester, NY)
Application Number:	11/869,170
Patent Claims:	1. An immunoglobulin that specifically binds CD20, wherein said immunoglobulin comprises an immunoglobulin heavy chain comprising a variable heavy (V.sub.H) domain and an immunoglobulin light chain comprising a variable light (V.sub.L) domain, wherein said immunoglobulin is selected from the group consisting of: a) an immunoglobulin comprising a V.sub.H domain comprising the amino acid sequence set forth in SEQ ID NO:12 and a V.sub.L, domain comprising the amino acid sequence set forth in SEQ ID NO:10; b) an immunoglobulin comprising the V.sub.H domain comprising the amino acid sequence set forth in SEQ ID NO:13 and a V.sub.Ldomain comprising the amino acid sequence set forth in SEQ ID NO:10; c) an immunoglobulin comprising a V.sub.H domain comprising the amino acid sequence set forth in SEQ ID NO:14 and a V.sub.L, domain comprising the amino acid sequence set forth in SEQ ID NO:10; d an immunoglobulin com risin a V domain comprising the amino acid sequence set forth in SEQ ID NO:15 and a V.sub.L, domain comprising the amino acid sequence set forth in SEQ ID NO:10; e) an immunoglobulin comprising a V.sub.H domain comprising the amino acid sequence set forth in SEQ ID NO:16 and a V.sub.L, domain comprising the amino acid sequence set forth in SEQ ID NO:10; f) an immunoglobulin comprising a V.sub.H domain comprising the amino acid sequence set forth in SEQ ID NO:17 and a V.sub.L domain comprising the amino acid sequence set forth in SEQ ID NO:10; g) an immunoglobulin com risin a V.sub.H domain comprising the amino acid sequence set forth in SEQ ID NO:18 and a V.sub.L domain comprising the amino acid sequence set forth in SEQ ID NO:10; h) an immunoglobulin comprising a V.sub.H domain comprising the amino acid sequence set forth in SEQ ID NO:13 and a V.sub.L domain comprising the amino acid sequence set forth in SEQ ID NO:11; and i) an immunoglobulin comprising a V.sub.H domain comprising the amino acid sequence set forth in SEQ ID NO:16 and a V.sub.L domain comprising the amino acid sequence set forth in SEQ ID NO:11. 2. The immunoglobulin of claim 1, wherein said immunoglobulin is an IgG1 kappa immunoglobulin. 3. The immunoglobulin of claim 2, wherein said IgG1 kappa immunoglobulin comprises a human IgG1 constant region within a heavy chain of said immunoglobulin and a human kappa constant region within a light chain of said immunoglobulin. 4. The immunoglobulin of claim 1, wherein said immunoglobulin exhibits increased complement-dependent cytotoxicity (CDC) as compared to rituximab. 5. The immunoglobulin of claim 1, further comprising a heterologous polypeptide fused thereto. 6. The immunoglobulin of claim 1, wherein said immunoglobulin is conjugated to an agent selected from the group consisting of a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a virus, a lipid, a biological response modifier, a pharmaceutical agent, and PEG. 7. A composition comprising the immunoglobulin of claim 1. 8. The composition of claim 7, further comprising a pharmaceutically acceptable carrier. 9. The immunoglobulin of claim 1, wherein said V.sub.H domain comprises the amino acid sequence set forth in SEQ ID NO:16 and said V.sub.L domain comprises the amino acid sequence set forth in SEQ ID NO:10.

Details for Patent 9,382,327

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2026-10-10
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2026-10-10
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017		2026-10-10